1-800-567-8911 or
604-682-5050
(Telephone interpreting in over 150 languages available)
Dacomitinib
Trade Name:
Vizimpro
Manufacturer/Distributor:
Pfizer Canada ULC
Classification:
Tyrosine kinase inhibitor
Antineoplastic agent
ATC Class:
L01EX47 - dacomitinib
Status:
active
Notice of Compliance (yyyy/mm/dd):
2019/02/22
Date Marketed in Canada (yyyy/mm/dd):
2019/04/22
Presentation:
Tablet: 15 mg. DIN: 02486024
Tablet: 30 mg. DIN: 02486032
Tablet: 45 mg. DIN: 02486040
Comments:
First-line treatment of non-small cell lung cancer in adults.
Back to:
Drug Product Listings 
